CLINICAL TRIALS PROFILE FOR BREXUCABTAGENE AUTOLEUCEL
✉ Email this page to a colleague
All Clinical Trials for brexucabtagene autoleucel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02601313 ↗ | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Active, not recruiting | Kite, A Gilead Company | Phase 2 | 2015-11-09 | The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL) |
| NCT02614066 ↗ | A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) | Active, not recruiting | Kite, A Gilead Company | Phase 1/Phase 2 | 2016-03-07 | The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). |
| NCT02625480 ↗ | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | Kite, A Gilead Company | Phase 1/Phase 2 | 2016-02-01 | The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). |
| NCT03624036 ↗ | Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Active, not recruiting | Kite, A Gilead Company | Phase 1 | 2018-11-15 | The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL). |
| NCT03642626 ↗ | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Recruiting | Masonic Cancer Center, University of Minnesota | 2018-12-18 | This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately. | |
| NCT04880434 ↗ | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Recruiting | Kite, A Gilead Company | Phase 2 | 2021-04-27 | The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for brexucabtagene autoleucel
Condition Name
| Condition Name for brexucabtagene autoleucel | |
| Intervention | Trials |
| Acute Lymphoblastic Leukemia | 3 |
| Relapsed/Refractory Mantle Cell Lymphoma | 2 |
| Mantle Cell Lymphoma | 1 |
| Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for brexucabtagene autoleucel
Trials by Country
Clinical Trial Progress for brexucabtagene autoleucel
Clinical Trial Phase
Clinical Trial Sponsors for brexucabtagene autoleucel
Sponsor Name
